Meet your 2019 best and worst biopharma CEOs
Every year, STAT’s Adam Feuerstein invites readers to vote on the best and worst drug industry CEOs, and the results for 2019 are in.
The public’s choice for best CEO presided over an FDA approval, a pivotal success in the clinic, and the steady transformation of a groundbreaking idea into a series of actual medicines.
And, in the close race for worst, the chosen executive had a year marked with confusion, controversy, and an ever-present sense that all of this could have been avoided with a little creativity.
Read more.
The public’s choice for best CEO presided over an FDA approval, a pivotal success in the clinic, and the steady transformation of a groundbreaking idea into a series of actual medicines.
And, in the close race for worst, the chosen executive had a year marked with confusion, controversy, and an ever-present sense that all of this could have been avoided with a little creativity.
Read more.
.png)
No hay comentarios:
Publicar un comentario